Sage Therapeutics Inc (SAGE)
32.11
+0.18 (+0.56%)
USD |
NASDAQ |
May 27, 15:54
Sage Therapeutics Total Liabilities (Quarterly): 87.20M for March 31, 2022
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2022 | 87.20M |
| December 31, 2021 | 96.26M |
| September 30, 2021 | 91.53M |
| June 30, 2021 | 85.96M |
| March 31, 2021 | 77.42M |
| December 31, 2020 | 86.91M |
| September 30, 2020 | 81.05M |
| June 30, 2020 | 87.33M |
| March 31, 2020 | 95.77M |
| December 31, 2019 | 139.50M |
| September 30, 2019 | 122.66M |
| June 30, 2019 | 112.67M |
| March 31, 2019 | 103.38M |
| December 31, 2018 | 89.73M |
| September 30, 2018 | 58.49M |
| June 30, 2018 | 51.72M |
| March 31, 2018 | 41.38M |
| Date | Value |
|---|---|
| December 31, 2017 | 54.46M |
| September 30, 2017 | 51.03M |
| June 30, 2017 | 33.11M |
| March 31, 2017 | 32.72M |
| December 31, 2016 | 36.01M |
| September 30, 2016 | 22.56M |
| June 30, 2016 | 18.42M |
| March 31, 2016 | 16.01M |
| December 31, 2015 | 15.32M |
| September 30, 2015 | 10.31M |
| June 30, 2015 | 11.02M |
| March 31, 2015 | 8.968M |
| December 31, 2014 | 7.78M |
| September 30, 2014 | 5.044M |
| June 30, 2014 | 96.44M |
| March 31, 2014 | 3.124M |
| December 31, 2013 | 40.07M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
33.11M
Minimum
Jun 2017
139.50M
Maximum
Dec 2019
82.38M
Average
87.06M
Median
Total Liabilities (Quarterly) Benchmarks
| Biogen Inc | 12.39B |
| Agios Pharmaceuticals Inc | 128.41M |
| Regeneron Pharmaceuticals Inc | 6.434B |
| Moderna Inc | 10.53B |
| Altimmune Inc | 20.79M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.706B |
| Shareholders Equity (Quarterly) | 1.619B |
| Current Ratio | 21.65 |